HONG KONG, Aug 18, 2023 - (ACN Newswire) - On August 16, Legend Capital's portfolio company, Gambol Pet (301498.SZ), was successfully listed on the ChiNext Market of the Shenzhen Stock Exchange. Gambol Pet plans to issue 40,004,500 shares at an offering price of RMB39.99 per share, with an estimated total fundraising of approximately RMB1.6 billion.
Engaged in the R&D, production and sales of pet food and providing multi-series products mainly for dogs and cats, Gambol Pet was founded in 2006 and is a leading pet food company in China. The company started with overseas OEM/ODM businesses and has gradually become a recognized supplier for international enterprises such as Walmart and Spectrum Brands. With the rapid growth of the pet food market in China, Gambol Pet has systematically expanded its presence in the Chinese market since 2013 and established its own brand, Myfoodie, which achieved full-category coverage in pet food, including pet staple food, snacks and health care products.
As one of the leading companies in the pet food industry, Gambol Pet adheres to the concept of "Global Vision, Continuous Innovation" and is committed to producing nutritious and healthy pet food that consumers need. Through its reliable product quality, continuous innovation and efficient sales network, the company made the best of the opportunity of the rapid expansion of the pet food demand in China and has formed a core lineup of proprietary brands with Myfoodie at the center.
Legend Capital invested in Gambol Pet in 2019 and 2020 and helped the company transform from an export-oriented OEM enterprise to a leading pet food enterprise in China driven by its own brand business. After the investment, Legend Capital provided value-added services to the company in various dimensions to support its business at home and abroad, including supply chain resource introduction, business sales channel connection, financial and legal compliance, and talent introduction.
QIN Hua, Chairman and CEO of Gambol Pet, said: "Gambol Pet will take the listing as an opportunity to firmly grasp the strategic window of the rapid development of the pet industry in China. We will adapt to the changes and dynamic trends in pet culture, consumer upgrades, and consumption concepts and continue increasing our products' market share in domestic and overseas markets. Simultaneously, by continuing to accelerate our global expansion and build our global advantages in technologies, talents, markets, and supply chains, we will keep moving forward and strive to become a highly innovative international enterprise with substantial growth, as well as a leading player in the global pet food industry."
Raymond CHEN, Co-Chief Investment Officer of Legend Capital, said: "With the continuous improvement of people's living standards, more and more people are getting emotionally attached to pets. The pet industry in China is in its early stages and enjoys broad prospects for future development. Gambol Pet adheres to continuous innovation and emphasizes proprietary brands. Through independent R&D and product innovation, it has formed its core brand, Myfoodie, which surpassed many imported brands and helped Gambol Pet consolidate its leading position in the pet food industry. Mr. QIN Hua, Chairman of the company, is an outstanding entrepreneur with both local experience and a global vision, and we are proud of the team for achieving this remarkable achievement. Congratulations to Gambol Pet on its successful listing."
About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.
It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.
Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.
For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).
The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.
For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Topic: Press release summary
Source: Legend Capital
Sectors: PE, VC & Alternatives
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Dec 19, 2023 15:45 HKT/SGT
Legend Capital Portfolio Company ZKH Lists on the New York Stock Exchange Successfully
|Oct 10, 2023 13:55 HKT/SGT
Co-led by Legend Capital, Leadrive Completes Series D Financing Round
|Sept 27, 2023 15:19 HKT/SGT
Legend Capital Portfolio Company TUHU Car Lists on the Main Board of the HKEX Successfully
|Aug 18, 2023 20:09 HKT/SGT
Legend Capital Portfolio: Nuclei, the World's First RISC-V CPU IP Vendor, Accomplishes ISO 26262 ASIL-D Product Certificate
|July 31, 2023 19:48 HKT/SGT
Exploring New Collaborative Opportunities! The Indonesia-China Healthcare and Biotech Investment Forum Successfully Held
|July 14, 2023 16:17 HKT/SGT
One More IPO of Legend Capital: Medical Device Supply Chain Service Provider GKHT Medical Goes Public Successfully
|May 4, 2023 16:15 HKT/SGT
Empowering R&D in Special Diseases, "Next Generation" CRO Company TriApex Completes Series C with Hundreds of Millions of CNY, Led by Legend Capital
|Mar 31, 2023 09:28 HKT/SGT
Rxilient Biotech and Junshi Biosciences form Joint Venture to develop and commercialize Toripalimab in Southeast Asia
|Feb 16, 2023 17:09 HKT/SGT
Led by Legend Capital, Macrolux Completes Nearly CNY100 million Series A Round
|Feb 15, 2023 18:58 HKT/SGT
Innovation is the Key Benchmark, Focus on Four Healthcare Industry Sub-Sectors in 2023, Says Jafar Wang of Legend Capital
|More news >>